Register

Company Profile

Sourcing Inquiry Logo Nuvisan GmbH

Nuvisan GmbH

Regions
Europe, South America, …
Regions
Europe, South America, Worldwide
Countries
Germany, Spain, …
Countries
Germany, Spain, France, Argentina, Austria, Belgium, Chile, Croatia, Ecuador, Hungary, Italy, Netherlands, Peru, Russia, Switzerland, United Kingdom
Size
250-500
Specialty
Human Medicines, Biopharmaceuticals, …
Specialty
Human Medicines, Biopharmaceuticals, Generics, Medical Devices
Service category
Contract manufacturing, filling and packaging, Pharmaceutical process development and validation, …
Service category
Contract manufacturing, filling and packaging, Pharmaceutical process development and validation, Formulation development and drug delivery, GMP audit services, GLP services, Clinical development and testing, clinical CRO, Analytical laboratory and testing services, Regulatory services - CMC writing - medical writing, Pharmacovigilance and QPPV services, Warehousing, storage, sampling, logistics and transport
Content posted and uploaded by users. Want to add your company?
Your company? Get access to this profile.

NUVISAN acquires Essex Pharma Development

Neu-Ulm/Waltrop, June 1, 2011 – Essex Pharma Development GmbH has a new owner. On June 1 The NUVISAN Group purchased Essex Pharma research institute from the MSD corporate group to include the transfer of all employees as part of the acquisition Effective immediately, the company will be jointly managed by Dr. Dietrich Bruchmann, Managing Director of the NUVISAN Group and Dr. Frans Maris, who was Site Director and Head of the Pharmaceutical Analysis Laboratory at Essex Pharma Development.

Dr. Dietrich Bruchmann, Managing Director of the NUVISAN Group, is pleased to announce this latest acquisition: “We are consistently growing NUVISAN into a powerful pharmaceutical service provider with three divisions: Laboratory Services, Early Clinical Development and Late Clinical Development. Our acquisition of Essex Pharma Development GmbH takes us one step closer to our goals. The company fits in perfectly with our strategy: in both its business focus and its highly qualified employees. By rounding out and extending our service portfolio, we will further reinforce our market position in laboratory services.” At the end of 2010, NUVISAN acquired FOCUS Clinical Drug Development GmbH to substantially strengthen and sustain its Early Clinical Development business.
Essex Pharma Development GmbH specialties include pharmaceutical analytics (to include large scale stability programs), as well as bioanalytics. In 2008, the development institute – located in Waltrop near Dortmund – was acquired by Merck & Co as part of the acquisition of the former Schering-Plough Corporation. Outside of the USA and Canada, the new Merck & Co. Inc. takes the corporate name “MSD.” The corporation is one of the world’s largest providers of innovative medications, vaccines, biological therapeutic preparations, consumer health products and veterinarian health products.

Essex Pharma Development GmbH specialties include pharmaceutical analytics (to include large scale stability programs), as well as bioanalytics. In 2008, the development institute – located in Waltrop near Dortmund – was acquired by Merck & Co as part of the acquisition of the former Schering-Plough Corporation. Outside of the USA and Canada, the new Merck & Co. Inc. takes the corporate name “MSD.” The corporation is one of the world’s largest providers of innovative medications, vaccines, biological therapeutic preparations, consumer health products and veterinarian health products.

Dr. Matthias Meise, Chairman of the ADCURAM Group AG, who as a corporate partner is actively involved in promoting the sustained growth of the NUVISAN Group, also sees this change of ownership as proof of the success of the corporation’s growth strategy: “NUVISAN has earned an excellent market reputation. This is now being rewarded by a strategic partnership with one of the world’s leading pharmaceutical companies. For ADCURAM, the acquisition of Essex Pharma Development also has strategic importance to significantly develop our capabilities in the Pharmaceutical Services business field. Therefore, in addition to the Essex Pharma acquisition we are also pursuing a series of other larger outsourcing deals with international pharmaceutical companies.“

About the NUVISAN Pharma Services Group
The NUVISAN Group is a successful, globally active and independent Clinical Research Organization (CRO), which conducts clinical research Phases I through III with a special focus on Oncology. Well over 2,500 pharmaceutical studies have been conducted since the company was founded. Along with complementary divisions focusing on bioanalytics, biopharmaceuticals, pharmaceutical analysis, stability testing and clinical trial supply production and packaging, the Nuvisan Group is able to offer comprehensive services in all areas of clinical pharmaceutical development from a single source. Founded in 1979 and headquartered in Neu-Ulm, Germany, the approx. 450 highly qualified employees of the NUVISAN Group around the world provide the pharmaceutical industry with the experience and expertise needed in todays competitive environment. In addition to NUVISAN GmbH, other companies belonging to the NUVISAN Group include FOCUS Clinical Drug Development GmbH and Essex Pharma Development GmbH. NUVISAN has been a member of the ADCURAM Group AG since May 11, 2010.



 

Sourcing this company's services?

Send inquiry anonymously »

Or add this Company to
Sourcing cart